» Articles » PMID: 28199980

PD-L1 Up-regulation in Melanoma Increases Disease Aggressiveness and is Mediated Through MiR-17-5p

Abstract

PD-L1 is expressed by a subset of patients with metastatic melanoma (MM) with an unfavorable outcome. Its expression is increased in cells resistant to BRAF or MEK inhibitors (BRAFi or MEKi). However, the function and regulation of expression of PD-L1 remain incompletely understood.After generating BRAFi- and MEKi-resistant cell lines, we observed marked up-regulation of PD-L1 expression. These cells were characterized by a common gene expression profile with up-regulation of genes involved in cell movement. Consistently, in vitro they showed significantly increased invasive properties. This phenotype was controlled in part by PD-L1, as determined after silencing the molecule. Up-regulation of PD-L1 was due to post-transcriptional events controlled by miR-17-5p, which showed an inverse correlation with PD-L1 mRNA. Direct binding between miR-17-5p and the 3'-UTR of PD-L1 mRNA was demonstrated using luciferase reporter assays.In a cohort of 80 BRAF-mutated MM patients treated with BRAFi or MEKi, constitutive expression of PD-L1 in the absence of immune infiltrate, defined the patient subset with the worst prognosis. Furthermore, PD-L1 expression increased in tissue biopsies after the metastatic lesions became resistant to BRAFi or MEKi. Lastly, plasmatic miR-17-5p levels were higher in patients with PD-L1+ than PD-L1- lesions.In conclusion, our findings indicate that PD-L1 expression induces a more aggressive behavior in melanoma cells. We also show that PD-L1 up-regulation in BRAFi or MEKi-resistant cells is partly due to post-transcriptional mechanisms that involve miR-17-5p, suggesting that miR-17-5p may be used as a marker of PD-L1 expression by metastatic lesions and ultimately a predictor of responses to BRAFi or MEKi.

Citing Articles

The Double-Edged Sword Property of Mesenchymal Stem Cell-Derived Exosomal microRNAs in Colorectal Cancer.

Yao H, Sun C, Wang C, Liu J, Li Y, Li L Turk J Gastroenterol. 2024; 35(10):755-762.

PMID: 39412096 PMC: 11465186. DOI: 10.5152/tjg.2024.23541.


MicroRNA-enriched exosome as dazzling dancer between cancer and immune cells.

Hsu C, Ahmed A, Bansal P, Hjazi A, Al-Hetty H, Qasim M J Physiol Biochem. 2024; 80(4):811-829.

PMID: 39316240 DOI: 10.1007/s13105-024-01050-x.


Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy.

Vaxevanis C, Bachmann M, Seliger B J Immunother Cancer. 2024; 12(8).

PMID: 39209767 PMC: 11367391. DOI: 10.1136/jitc-2024-009774.


Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential.

Afsar S, Syed R, Khojali W, Masood N, Osman M, Jyothi J Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):297-317.

PMID: 39167168 DOI: 10.1007/s00210-024-03366-3.


Integrative analysis of genomic and epigenomic regulation reveals miRNA mediated tumor heterogeneity and immune evasion in lower grade glioma.

Yang Z, Liu X, Xu H, Teschendorff A, Xu L, Li J Commun Biol. 2024; 7(1):824.

PMID: 38971948 PMC: 11227553. DOI: 10.1038/s42003-024-06488-9.


References
1.
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D . Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014; 372(1):30-9. DOI: 10.1056/NEJMoa1412690. View

2.
Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

3.
Atefi M, Avramis E, Lassen A, Wong D, Robert L, Foulad D . Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014; 20(13):3446-57. PMC: 4079734. DOI: 10.1158/1078-0432.CCR-13-2797. View

4.
Tang M, Wang Y, Guo S, Han S, Li H, Jin S . CD24 expression predicts poor prognosis for patients with cutaneous malignant melanoma. Int J Clin Exp Med. 2015; 7(11):4337-41. PMC: 4276209. View

5.
Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi F . The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2012; 19(3):598-609. DOI: 10.1158/1078-0432.CCR-12-2731. View